MIRA INFORM REPORT
|
Report Date : |
18.05.2013 |
IDENTIFICATION DETAILS
|
Name : |
RANDOX LABORATORIES LTD. |
|
|
|
|
Registered Office : |
Ardmore 55 Diamond Road
Crumlin, BT29 4QY County Antrim County |
|
|
|
|
Country : |
United Kingdom |
|
|
|
|
Financials (as on) : |
31.12.2011 |
|
|
|
|
Date of Incorporation : |
20.04.1982 |
|
|
|
|
Com. Reg. No.: |
NI015738 |
|
|
|
|
Legal Form : |
Private Independent |
|
|
|
|
Line of Business : |
Subject is ) is a pharmaceutical and healthcare company. |
|
|
|
|
No. of Employees : |
809 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March, 31st, 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
United Kingdom |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
UNITED KINGDOM - ECONOMIC OVERVIEW
The UK, a leading trading power and financial center, is the
second largest economy in Europe after Germany. Over the past two decades, the
government has greatly reduced public ownership and contained the growth of
social welfare programs. Agriculture is intensive, highly mechanized, and
efficient by European standards, producing about 60% of food needs with less
than 2% of the labor force. The UK has large coal, natural gas, and oil
resources, but its oil and natural gas reserves are declining and the UK became
a net importer of energy in 2005. Services, particularly banking, insurance,
and business services, account by far for the largest proportion of GDP while
industry continues to decline in importance. After emerging from recession in
1992, Britain's economy enjoyed the longest period of expansion on record
during which time growth outpaced most of Western Europe. In 2008, however, the
global financial crisis hit the economy particularly hard, due to the
importance of its financial sector. Sharply declining home prices, high
consumer debt, and the global economic slowdown compounded Britain's economic
problems, pushing the economy into recession in the latter half of 2008 and
prompting the then BROWN (Labour) government to implement a number of measures
to stimulate the economy and stabilize the financial markets; these include
nationalizing parts of the banking system, temporarily cutting taxes,
suspending public sector borrowing rules, and moving forward public spending on
capital projects. Facing burgeoning public deficits and debt levels, in 2010
the CAMERON-led coalition government (between Conservatives and Liberal
Democrats) initiated a five-year austerity program, which aimed to lower
London's budget deficit from over 10% of GDP in 2010 to nearly 1% by 2015. In
November 2011, Chancellor of the Exchequer George OSBORNE announced additional
austerity measures through 2017 because of slower-than-expected economic growth
and the impact of the euro-zone debt crisis. The CAMERON government raised the
value added tax from 17.5% to 20% in 2011. It has pledged to reduce the
corporation tax rate to 21% by 2014. The Bank of England (BoE) implemented an
asset purchase program of up to £375 billion (approximately $605 billion) as of
December 2012. During times of economic crisis, the BoE coordinates interest
rate moves with the European Central Bank, but Britain remains outside the
European Economic and Monetary Union (EMU). In 2012, weak consumer spending and
subdued business investment weighed on the economy. GDP fell 0.1%, and the
budget deficit remained stubbornly high at 7.7% of GDP. Public debt continued
to increase.
|
Source
: CIA |
Company name and address
RANDOX LABORATORIES LTD.
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||
Business Description
Randox Laboratories Ltd. (Randox) is a pharmaceutical and
healthcare company. It develops and manufactures diagnostic kits for
biochemistry laboratories. Its major product categories include biochip
analyzers, biochip immunoassays, biochip molecular diagnostics, cardiovascular
biomarkers and regents, clinical chemistry analyzers and diagnostic reagents.
The company operates along with its major subsidiaries including Randox Food
Diagnostics, Randox Toxicology, Randox Life Sciences, Randox Health, Randox Testing
Services and Randox Pharma Services. It also operates an online store. The
company’s products are used in more than 145 countries worldwide by hospital
laboratories, forensic laboratories, A and E units, food and wine testing
laboratories, sports testing organizations, horse racing authorities,
veterinary clinics, contract research organizations and pharmaceutical
companies. Randox is headquartered in Crumlin, Antrim, the UK.
Industry
|
ANZSIC 2006: |
6999 - Other Professional, Scientific and Technical
Services Not Elsewhere Classified |
|
NACE 2002: |
|
|
NAICS 2002: |
|
|
UK SIC 2003: |
|
|
UK SIC 2007: |
|
|
US SIC 1987: |
Key Executives
|
Name |
Title |
|
Finance Director |
|
|
Chris Henry |
Marketing Manager |
|
Stephen Peter Fitzgerald |
Secretary |
|
W. Foy |
IT Manager |
|
Health & Safety Manager |
News
|
Title |
Date |
|
N. Ireland firms push for new Saudi deals |
13-May-2013 |
|
N. Ireland firms push for new Saudi deals |
13-May-2013 |
|
Randox Licenses sPLA2 CVD Risk Test from Aterovax |
1-May-2013 |
|
40 RANDOX |
30-Apr-2013 |
|
Our top companies make firm progress |
23-Apr-2013 |
|
BNP control comes ready-to-use |
1-Apr-2013 |
Financial Summary
FYE:
31-Dec-2011 USD (mil)
|
Key Figures |
|
|
Current Assets |
67.65 |
|
Fixed Assets |
37.22 |
|
Total Liabilities |
46.10 |
|
Net Worth |
15.07 |
|
Key Ratios |
|
|
Current Ratio |
1.47 |
|
Acid Test |
0.97 |
|
Debt Gearing |
194.18 |
Registered No.(UK): NI015738
1 - Profit & Loss Item Exchange Rate: USD 1 = GBP 0.623776
2 - Balance Sheet Item Exchange Rate:
USD 1 = GBP 0.6434593
|
|
|
|
|
||||||||||||||||||||||||||||||
|
ANZSIC
2006 Codes: |
||
|
6999 |
- |
Other Professional,
Scientific and Technical Services Not Elsewhere Classified |
|
NACE
2002 Codes: |
||
|
7487 |
- |
Other business activities
not elsewhere classified |
|
NAICS
2002 Codes: |
||
|
5619 |
- |
Other Support Services |
|
US
SIC 1987: |
||
|
7389 |
- |
Business Services, Not
Elsewhere Classified |
|
UK
SIC 2003: |
||
|
7487 |
- |
Other business activities
not elsewhere classified |
|
UK
SIC 2007: |
||
|
8299 |
- |
Other business support
service activities n.e.c. |
Founded in 1982 by Dr. Peter FitzGerald,
Randox Laboratories Ltd. is engaged in the development of some of the most
revolutionary technologies in the field of medical diagnostics. Privately
owned, Randox develops, manufactures and markets a wide range of clinical
diagnostic products for laboratory medicine. Its core products and services
include Biochip Array technology, clinical chemistry automation systems,
external quality assurance schemes, Internet driven quality assurance systems,
quality control materials, antibodies, recombinant proteins, clinical reagents
and environmental diagnostics. Randox maintains sales and distribution
agreements in 130 countries and international offices with representation in
Africa, Asia, Australia, Europe, North America and South America. The company employs
more than 600 people, including 185 research scientists. Randox Laboratories
Ltd. maintains an office in Crumlin, County Antrim. (Updated by OneSource
Information Services)
More Business Descriptions
Randox Laboratories Ltd is
primarily engaged in providing some nursing and/or health-related care to
patients who do not require the degree of care and treatment that a skilled or
intermediate care facility is designed to provide. Patients in these
facilities, because of their mental or physical condition, require some nursing
care, including the administering of medications and treatments or the supervision
of self-administered medications in accordance with a physician's orders.
Manufacturer of chemical
preps
Research and Laboratory Based
Activities
Randox Laboratories Ltd.
(Randox) is a pharmaceutical and healthcare company. It develops and manufactures
diagnostic kits for biochemistry laboratories. Its major product categories
include biochip analyzers, biochip immunoassays, biochip molecular diagnostics,
cardiovascular biomarkers and regents, clinical chemistry analyzers and
diagnostic reagents. The company operates along with its major subsidiaries
including Randox Food Diagnostics, Randox Toxicology, Randox Life Sciences,
Randox Health, Randox Testing Services and Randox Pharma Services. It also
operates an online store. The company’s products are used in more than 145
countries worldwide by hospital laboratories, forensic laboratories, A and E
units, food and wine testing laboratories, sports testing organizations, horse
racing authorities, veterinary clinics, contract research organizations and
pharmaceutical companies. Randox is headquartered in Crumlin, Antrim, the UK.
After 25 years in the
diagnostics healthcare business, Randox is now firmly implanted as a significant
investor to improving healthcare technology. Throughout the last 25 years
Randox has developed and manufactured high quality diagnostic kits mainly for
biochemistry laboratories and more recently endocrinology. Randox's clinical
products can be found in almost every country throughout the world, in fact,
wherever there is a need for disease diagnosis. Consequently, the role that
Randox products play in healthcare decisions is increasing every day. It is
evident that clinical diagnostics are taking centre-stage in the fight for
improved health. It is commonly acknowledged that as much as 70% of the
information used by medical personnel to make a diagnosis is information
sourced from the laboratory. Randox is helping through research and development
with improved diagnostic systems to present more patient information to the
medical professionals. That is to say, to help empower medical staff with a
more complete diagnostic patient profile. This is why Randox designed the very
exciting biochip array system EvidenceR and Evidence InvestigatorT diagnostic
systems that will change the way we think of diagnostic testing. Instead of a
patient sample needing to be subdivided for each test result, EvidenceR and
Evidence InvestigatorT offer a diagnostic patient profile with each patient
sample. So now the patient's need becomes the focus and 1from Randox deliver
the multiple results needed for improved diagnosis.
|
|
|
Auditor: |
Deloitte LLP |
|
Bank: |
Northern Bank Ltd. |
|
Auditor: |
Deloitte LLP |
|
Auditor History |
|
|
Deloitte LLP |
31-Dec-2011 |
|
Deloitte LLP |
31-Dec-2010 |
|
Deloitte LLP |
31-Dec-2009 |
|
Deloitte LLP |
31-Dec-2008 |
|
Deloitte And Touche LLP |
31-Dec-2007 |
|
|
|
|
|
GBP(mil) |
|
Audit Fees: |
0.0 |
|
Non Audit Fees: |
0.0 |
|
Audit Fiscal Year: |
12-31-2011 |
Competitors Report
|
CompanyName |
Location |
Employees |
Ownership |
|
Celsis International Ltd. |
London, United Kingdom |
2 |
Private |
|
Instrumentation Laboratory |
Bedford, Massachusetts, United States |
1,000 |
Private |
|
Ray Biotech |
Norcross, Georgia, United States |
20 |
Private |
|
SeraCare Life Sciences, Inc. |
Milford, Massachusetts, United States |
193 |
Public |
Board of Directors
|
|
|
|||
|
Secretary |
Director/Board Member |
|||
|
|||||
|
Director |
Director/Board Member |
|
||
|
Director |
Director/Board Member |
|
||
|
|||||
Executives
|
|
|
|||
|
Health & Safety Manager |
Environment/Safety Executive |
|||
|
Secretary |
Company Secretary |
|||
|
|||||
|
Finance Director |
Finance Executive |
|
||
|
HR Manager |
Human Resources Executive |
|
||
|
Training Manager |
Training Executive |
|
||
|
Global Manager - Pharma Services Division |
International Executive |
|
||
|
Marketing Manager |
Marketing Executive |
|
||
|
IT Manager |
Information Executive |
|
||
|
Manager |
Other |
|
||
Directors and Shareholders Report
|
Main Office Address: |
Tel: 028 9442 2413 |
Annual Return Date: 01
Feb 2013 |
|
Individual Directors |
|||||||
|
|
|||||||
|
Name |
Status |
DOB |
Filed Address |
Appointment Date |
Resignation Date |
Summary of Directorships |
|
|
Current |
24 Jul 1962 |
Huntly House, Huntly Rd, |
21 Dec 2006 |
NA |
Current:38 |
|
|
|
Current |
02 Aug 1950 |
Ardmore 55 Diamond Road, Crumlin, |
20 Apr 1982 |
NA |
Current:11 |
|
|
|
Previous |
28 Nov 1952 |
Ardmore 55 Diamond Road, Crumlin, |
20 Apr 1982 |
21 Dec 2006 |
Current:0 |
|
|
|
Previous |
26 Sep 1923 |
Ardmore, 55 Diamond Road, |
20 Apr 1982 |
02 Aug 2010 |
Current:0 |
|
|
|
Previous |
14 May 1923 |
Ardmore 55 Diamond Road, Crumlin, |
20 Apr 1982 |
02 Aug 2010 |
Current:0 |
|
|
|
|
|
||||||
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
Corporate Directors |
|
|
|
There are no corporate directors for this company. |
|
|
|
Individual Secretaries |
|||||||
|
|
|||||||
|
Name |
Status |
DOB |
Filed Address |
Appointment Date |
Resignation Date |
Summary of Directorships |
|
|
Current |
NA |
55 Diamond Road, Crumlin, |
20 Apr 1982 |
NA |
Current:1 |
|
|
|
|
|
||||||
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
Corporate Secretaries |
|
|
|
There are no corporate secretaries for this company. |
|
|
|
Individual Shareholders |
||||||
|
|
||||||
|
There are no individual shareholders for this company. |
||||||
|
|
||||||
|
|
||||||
|
|
|
|
|
|
|
|
|
Corporate Shareholders |
|||||||
|
|
|||||||
|
Company Name |
Registration Number |
Share Details |
Share Type |
# of Shares |
Share Price (GBP) |
Share Value (GBP) |
% of Total Shares |
|
NI614690 |
88200 Ordinary GBP 1.00 |
Ordinary |
88,200 |
1.00 |
88,200.00 |
100.00 |
|
|
|
|||||||
News
|
N. Ireland
firms push for new Saudi deals |
13-May-2013 |
|
N. Ireland
firms push for new Saudi deals |
13-May-2013 |
|
Randox
Licenses sPLA2 CVD Risk Test from Aterovax |
01-May-2013 |
|
40 RANDOX |
30-Apr-2013 |
|
Our top
companies make firm progress |
23-Apr-2013 |
|
BNP control
comes ready-to-use |
01-Apr-2013 |
|
Recession
had little impact on the monied |
11-Mar-2013 |
|
Interlaboratory
program interprets QC results |
01-Mar-2013 |
|
US Patent Issued
to Randox Laboratories on Feb. 12 for "Assay Device Processing Apparatus
and Method" (British Inventors) |
15-Feb-2013 |
|
Appointments |
04-Feb-2013 |
|
Laura
Slevin has been |
04-Feb-2013 |
Annual Profit & Loss
Financials in: USD (mil)
Except for share items (millions) and per share items
(actual units)
|
|
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
31-Dec-2007 |
|
Period Length |
52 Weeks |
52 Weeks |
52 Weeks |
52 Weeks |
52 Weeks |
|
Filed Currency |
GBP |
GBP |
GBP |
GBP |
GBP |
|
Exchange Rate (Period
Average) |
0.623776 |
0.647573 |
0.641508 |
0.545576 |
0.499878 |
|
Consolidated |
Yes |
Yes |
Yes |
Yes |
Yes |
|
|
|
|
|
|
|
|
Total Turnover |
110.0 |
92.2 |
98.8 |
96.9 |
93.0 |
|
Cost of Sales |
56.4 |
47.2 |
53.4 |
40.2 |
40.9 |
|
Gross Profit |
53.6 |
45.0 |
45.4 |
56.8 |
52.1 |
|
Depreciation |
3.1 |
3.2 |
4.2 |
4.5 |
4.6 |
|
Other Expenses |
53.1 |
41.3 |
41.3 |
43.5 |
44.5 |
|
Other Income |
4.6 |
1.9 |
2.8 |
2.7 |
3.6 |
|
Interest Paid |
1.8 |
1.6 |
1.6 |
3.6 |
3.9 |
|
Exceptional Income |
0.0 |
0.0 |
0.0 |
-0.8 |
0.0 |
|
Discontinued Operations |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Profit Before Taxes |
3.3 |
4.0 |
5.3 |
11.5 |
7.3 |
|
Tax Payable / Credit |
0.2 |
-0.5 |
2.8 |
-0.5 |
0.1 |
|
Extraordinary Items/Debits |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Dividends |
0.0 |
0.3 |
0.2 |
0.3 |
0.3 |
|
Profit After Taxes |
3.1 |
4.2 |
2.2 |
11.7 |
6.9 |
|
Minority Interests (Profit & Loss) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Audit Fees |
0.1 |
0.1 |
0.1 |
0.1 |
0.1 |
|
Non Audit Fees |
0.0 |
0.0 |
0.0 |
- |
- |
|
Number of Employees |
809 |
769 |
738 |
738 |
736 |
|
Wages |
29.7 |
27.5 |
- |
- |
30.1 |
|
Social Security Costs |
2.3 |
2.0 |
- |
- |
0.0 |
|
Other Pension Costs |
0.2 |
0.2 |
- |
30.2 |
0.2 |
|
Employees Remuneration |
32.2 |
29.7 |
27.6 |
30.2 |
30.3 |
|
Directors Remuneration |
0.2 |
0.5 |
0.5 |
0.5 |
0.6 |
|
Highest Paid Director |
0.2 |
0.2 |
0.3 |
0.3 |
0.4 |
Annual Balance Sheet
Financials in: USD (mil)
|
|
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
31-Dec-2007 |
|
Filed Currency |
GBP |
GBP |
GBP |
GBP |
GBP |
|
Exchange Rate |
0.643459 |
0.638712 |
0.619253 |
0.695531 |
0.502361 |
|
Consolidated |
Yes |
Yes |
Yes |
Yes |
Yes |
|
|
|
|
|
|
|
|
Land & Buildings |
17.4 |
15.1 |
9.8 |
8.8 |
11.3 |
|
Fixtures & Fittings |
1.8 |
1.2 |
1.1 |
1.2 |
2.4 |
|
Plant & Vehicles |
5.2 |
6.5 |
7.0 |
6.4 |
7.5 |
|
Total Tangible Fixed Assets |
24.5 |
22.8 |
17.9 |
16.3 |
21.1 |
|
Intangible Assets |
12.8 |
9.2 |
7.6 |
5.7 |
9.1 |
|
Investments |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Total Fixed Assets |
37.2 |
31.9 |
25.5 |
22.0 |
30.2 |
|
Stocks |
- |
- |
13.9 |
21.9 |
- |
|
Work in Progress |
- |
- |
0.0 |
0.0 |
- |
|
Total Stocks Work In Progress |
23.0 |
18.1 |
13.9 |
21.9 |
24.7 |
|
Trade Debtors |
17.9 |
18.3 |
19.3 |
17.3 |
17.3 |
|
Inter-Company Debtors |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Other Debtors |
12.3 |
7.3 |
4.5 |
2.1 |
1.0 |
|
Total Debtors |
30.1 |
25.6 |
23.8 |
19.4 |
18.3 |
|
Cash and Equivalents |
14.5 |
13.2 |
16.3 |
4.1 |
6.8 |
|
Other Current Assets |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Total Current Assets |
67.6 |
56.9 |
54.0 |
45.4 |
49.8 |
|
Total Assets |
104.9 |
88.9 |
79.5 |
67.4 |
80.0 |
|
Trade Creditors |
24.8 |
19.5 |
12.4 |
12.1 |
8.1 |
|
Bank Overdraft |
14.7 |
8.7 |
6.0 |
3.3 |
22.5 |
|
Inter-Company Creditors |
0.0 |
0.0 |
- |
0.0 |
0.0 |
|
Total Short Term Loans |
- |
- |
- |
16.1 |
2.8 |
|
Accruals/Deferred Income (Current Liability) |
1.5 |
3.1 |
1.4 |
0.8 |
3.0 |
|
Social Security/VAT |
1.0 |
1.1 |
0.8 |
0.7 |
0.7 |
|
Other Current Liabilities |
4.2 |
1.8 |
5.8 |
10.3 |
8.3 |
|
Total Current Liabilities |
46.1 |
34.2 |
26.4 |
43.3 |
45.4 |
|
Group Loans (Long Term Liability) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Director Loans (Long Term Liability) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Hire Purchase (Long Term Liability) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Leasing (Long Term Liability) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Total Hire Purchase Loans (Long Term Liability) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Other Long Term Loans |
29.3 |
26.7 |
26.0 |
0.3 |
12.4 |
|
Accruals/Deferred Income (Long Term Liability) |
0.0 |
0.0 |
0.0 |
0.6 |
0.0 |
|
Other Long Term Liabilities |
0.0 |
3.1 |
3.5 |
6.0 |
10.0 |
|
Total Long Term Liabilities |
29.3 |
29.8 |
29.5 |
6.9 |
22.5 |
|
Deferred Taxation |
1.7 |
1.5 |
- |
0.0 |
0.0 |
|
Other Provisions |
0.0 |
0.0 |
2.1 |
0.0 |
0.0 |
|
Total Provisions |
1.7 |
1.5 |
2.1 |
0.0 |
0.0 |
|
Issued Capital |
0.1 |
0.1 |
0.1 |
0.1 |
0.2 |
|
Share Premium Accounts |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Revaluation Reserve |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Retained Earnings |
27.7 |
23.2 |
21.4 |
17.1 |
12.0 |
|
Other Reserves |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Minority Interests (Balance Sheet) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Total Shareholders Funds |
27.8 |
23.3 |
21.6 |
17.2 |
12.2 |
|
Net Worth |
15.1 |
14.2 |
14.0 |
11.5 |
3.0 |
Annual Cash Flows
Financials in: USD (mil)
|
|
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
31-Dec-2007 |
|
Period Length |
52 Weeks |
52 Weeks |
52 Weeks |
52 Weeks |
52 Weeks |
|
Filed Currency |
GBP |
GBP |
GBP |
GBP |
GBP |
|
Exchange Rate (Period
Average) |
0.623776 |
0.647573 |
0.641508 |
0.545576 |
0.499878 |
|
Consolidated |
Yes |
Yes |
Yes |
Yes |
Yes |
|
|
|
|
|
|
|
|
Net Cash Flow From Operating Activities |
18.4 |
18.0 |
26.4 |
23.3 |
22.8 |
|
Net Cash Flow from ROI and Servicing of Finance |
-1.8 |
-1.6 |
-1.6 |
-3.6 |
-3.9 |
|
Taxation |
0.0 |
0.0 |
0.0 |
-0.4 |
-0.1 |
|
Capital Expenditures |
-21.0 |
-19.1 |
-13.9 |
-13.9 |
-13.2 |
|
Acquisitions and Disposals |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Paid Up Equity |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Management of Liquid Resources |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Net Cash Flow From Financing |
2.0 |
-1.0 |
11.8 |
-7.9 |
-4.4 |
|
Increase in Cash |
-2.4 |
-3.9 |
22.5 |
-2.5 |
1.2 |
Annual Ratios
Financials in: USD (mil)
|
|
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
31-Dec-2007 |
|
Period Length |
52 Weeks |
52 Weeks |
52 Weeks |
52 Weeks |
52 Weeks |
|
Filed Currency |
GBP |
GBP |
GBP |
GBP |
GBP |
|
Exchange Rate |
0.643459 |
0.638712 |
0.619253 |
0.695531 |
0.502361 |
|
Consolidated |
Yes |
Yes |
Yes |
Yes |
Yes |
|
|
|
|
|
|
|
|
Current Ratio |
1.47 |
1.67 |
2.05 |
1.05 |
1.10 |
|
Liquidity Ratio |
0.97 |
1.14 |
1.52 |
0.54 |
0.55 |
|
Stock Turnover |
4.64 |
5.16 |
7.36 |
3.47 |
3.75 |
|
Credit Period (Days) |
61.13 |
71.58 |
68.82 |
83.08 |
68.09 |
|
Working Capital by Sales |
20.20% |
24.38% |
26.98% |
2.79% |
4.74% |
|
Trade Credit by Debtors |
1.39 |
1.06 |
0.64 |
0.70 |
0.47 |
|
Return on Capital |
5.51% |
7.40% |
10.24% |
37.33% |
20.91% |
|
Return on Assets |
3.09% |
4.55% |
6.84% |
13.36% |
9.04% |
|
Profit Margin |
3.03% |
4.33% |
5.32% |
11.84% |
7.82% |
|
Return on Shareholders Funds |
11.63% |
17.34% |
25.24% |
52.28% |
59.53% |
|
Borrowing Ratio |
291.43% |
249.72% |
229.18% |
170.07% |
1,251.52% |
|
Equity Gearing |
26.53% |
26.26% |
27.11% |
25.55% |
15.19% |
|
Debt Gearing |
194.18% |
188.40% |
186.11% |
2.58% |
412.27% |
|
Interest Coverage |
1.90 |
2.51 |
3.20 |
3.17 |
1.86 |
|
Sales by Tangible Assets |
4.36 |
4.11 |
5.71 |
4.66 |
4.39 |
|
Average Remuneration per Employee |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Profit per Employee |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Sales per Employee |
0.1 |
0.1 |
0.1 |
0.1 |
0.1 |
|
Capital Employed per Employee |
0.1 |
0.1 |
0.1 |
0.0 |
0.0 |
|
Tangible Assets per Employee |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Total Assets per Employee |
0.1 |
0.1 |
0.1 |
0.1 |
0.1 |
|
Employee Remuneration by Sales |
29.23% |
32.20% |
27.94% |
31.11% |
32.61% |
|
Creditor Days (Cost of Sales Based) |
165.54 |
148.53 |
81.90 |
139.68 |
72.36 |
|
Creditor Days (Sales Based) |
84.89 |
76.10 |
44.25 |
57.87 |
31.84 |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.54.88 |
|
|
1 |
Rs.83.66 |
|
Euro |
1 |
Rs.70.58 |
INFORMATION DETAILS
|
Report Prepared
by : |
SDA |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.